Memorial Hermann Hospital

Summary

Memorial Hermann Hospital is a medical facility located in Houston, Texas. This center is recognized for care of Stroke, Heart Failure, Lung Cancer, Ovarian Cancer, HIV Infection and other specialties. Memorial Hermann Hospital is involved with conducting 242 clinical trials across 388 conditions. There are 37 research doctors associated with this hospital, such as Sean Savitz, Jay-Jiguang Zhu, MD, Abhijeet Dhoble, MD, and Dominick D'Aunno, MD.

Top PIs

Clinical Trials running at Memorial Hermann Hospital

Stroke

Ovarian Cancer

Heart Failure

Lung Cancer

Uterine Cancer

Atrial Fibrillation

Acute Kidney Injury

Cancer

Pancreatic Cancer

Gliosarcoma

Sovateltide

for Stroke

Extensive research is being conducted in search of neuroprotective agents for possible use in the acute phase of stroke and agents that can be used for neurorepair in later stages of stroke. Several trials have been conducted and are in progress using different pharmacological agents, but none of the studies involve the stimulation of ETB receptors to treat cerebral ischemic stroke. Sovateltide (IRL-1620, PMZ-1620) has been effective in animal models of cerebral ischemic stroke. Its safety and tolerability have been demonstrated in a human phase I study with 7 subjects. Clinical phase II and III results indicate that sovateltide is a novel, first-in-class, highly effective drug candidate for treating cerebral ischemic stroke. Safety and significant efficacy in improving the National Institutes of Health Stroke Scale (NIHSS), Modified Rankin scale (mRS), and Barthel index (BI) obtained in phase II and III studies in patients with cerebral ischemic stroke in India are convincing and encouraged us to investigate its safety and efficacy in cerebral ischemic stroke patients in the United States. Therefore, the plan is to conduct a phase III clinical study to evaluate the safety and efficacy of sovateltide therapy along with standard of care in patients of acute ischemic stroke.

Recruiting

2 awards

Phase 3

3 criteria

Left Atrial Appendage Occlusion vs. NOAC

for Atrial Fibrillation

The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion.

Recruiting

1 award

N/A

8 criteria

Endovascular Thrombectomy

for Stroke

STEP is a Randomized, Multifactorial, Adaptive Platform trial that seeks to optimize the care of patients with acute ischemic stroke (AIS) due to large (LVO) or medium vessel occlusions (MVO).

Recruiting

1 award

N/A

2 criteria